Pharmacotherapy of panic disorder: Differential efficacy from a clinical viewpoint

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL.8, 1998, Pages 30-38

  Den Boer, Johan A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BROFAROMINE; CLOMIPRAMINE; IMIPRAMINE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENELZINE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGORAPHOBIA; ANXIETY NEUROSIS; DRUG EFFICACY; HUMAN; PANIC; PRIORITY JOURNAL; REVIEW; SYMPTOMATOLOGY;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZODIAZEPINES; CONTROLLED CLINICAL TRIALS; HUMANS; MONOAMINE OXIDASE INHIBITORS; PANIC DISORDER; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 0031904155     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. Hoehn-Saric R, McCleod DR, Hipsley PA. Effect of fluvoxamine on panic disorder. J Clin Psychopharmacol 1993;13:321-326
2. Black DW, Wesner R, Bowers W, et al. A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 1993;50:44-50
3. Oehrberg PE, Christiansen K, Behnke AL, et al. Paroxetine in the treatment of panic disorder: a randomised double-blind, placebo-controlled study. Br J Psychiatry 1995;167:374-379
4. Lecrubier Y, Bakker A, Dunbar G, et al. A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Acta Psychiatr Scand 1997;95:145-152
5. Lecrubier Y, Judge R, and the Collaborative Paroxetine Panic Study Investigators. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Acta Psychiatr Scand 1997;95:153-160
6. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998;155:36-42
7. Wade AG, Lepola U, Koponen HJ, et al. The effect of citalopram in panic disorder. Br J Psychiatry 1997;170:549-553
8. Cross National Collaborative Panic Study, Second Phase Investigators. Drug treatment of panic disorder. Br J Psychiatry 1992;160:191-202
9. Schweizer E, Rickels K, Weiss S, et al. Maintenance drug treatment of panic disorder: results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry 1993;50:51-60
10. Andersch S, Rosenberg NK, Kullingsjo H, et al. Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder: a Scandinavian multicenter study. Acta Psychiatr Scand 1991;365:18-27
11. Ballenger JC, Burrows GD, DuPont RL, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial, I: efficacy in short-term treatment. Arch Gen Psychiatry 1988;45:413-422
12. Pecknold JC, Swinson RP, Kuch K, et al. Alprazolam in panic disorder and agoraphobia: results from a multicenter trial. Arch Gen Psychiatry 1988; 45:429-436
13. Tesar GE, Rosenbaum JF, Pollack MH, et al. Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 1991;52:69-76
14. Munjack DD, Crocker B, Cobe D. Alprazolam, propranolol and placebo in the treatment of panic disorder and agoraphobia with panic attacks. J Clin Psychopharmacol 1989;9:22-27
15. Lydiard RB, Lesser IM, Ballenger JC, et al. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol 1992;12:96-103
16. Noyes R Jr, Burrows GD, Reich JH, et al. Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry 1996;57:349-355
17. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 1992;12:251-261
18. Fahy TJ, O'Rourke D, Brophy J, et al. The Galway study of panic disorder. I: clomipramine and lofepramine in DSM-III-R panic disorder: a placebo-controlled trial. J Affect Disord 1992;25:63-76
19. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev 1995;8:819-844
20. Burrows GD, Judd FK, Norman TR. Long-term drug treatment of panic disorder. J Psychiatr Res 1993;27(1, suppl):111-125
21. Marchesi C, Ampollini P, Signifredi R, et al. The treatment of panic disorder in a clinical setting: a 12-month naturalistic study. Neuropsychobiology 1997;36:25-31
22. Sheehan DV, Beh MB, Ballenger JC, et al. Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Arch Gen Psychiatry 1980;37:51-59
23. Bakish D, Saxena BM, Bowen R, et al. Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropharmacol 1993;16(2, suppl): S77-S82
24. Van Vliet IM, Westenberg HGM, den Boer JA. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. Psychopharmacology (Berl) 1993;112:483-489
25. den Boer JA, Westenberg HGM, Kamerbeek WDJ, et al. Effect of serotonin uptake inhibitors in anxiety disorders; a double-blind comparison of clomipramine and fluvoxamine. Int Clin Psychopharmacol 1987;2:21-32
26. den Boer JA, Westenberg HGM. Effect of a serotonin and noradrenaline uptake inhibitor in panic disorders: a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 1988;3:59-74
27. den Boer JA, Westenberg HGM. Serotonin function in panic disorder: a double-blind, placebo-controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 1990;102:85-94
28. Van Vliet IM, den Boer JA, Westenberg HGM, et al. A double-blind comparative study of brofaromine and fluvoxamine in outpatients with panic disorder. J Clin Psychopharmacol 1996;16:299-306
29. Baumel B, Bielski R, Carman J, et al. Double-blind comparison of sertraline and placebo in patients with panic disorder. Poster presented at the 20th Collegium Internationale Neuro-Psychopharmacologicum; June 23-27, 1996; Melbourne, Australia
30. Bystritsky A, Rosen RM, Murphy KJ, et al. Double-blind pilot trial of desipramine versus fluoxetine in panic patients. Anxiety 1994/1995;1: 287-290
31. de Beurs E, van Balkom AJLM, Lange A, et al. Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone. Am J Psychiatry 1995;152:683-691
32. Pecknold J, Luthe L, Munjack D, et al. A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. J Clin Psychopharmacol 1994;14:314-321
33. Beauclair L, Fontaine R, Annable L, et al. Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 1994;14:111-118
34. Cox BJ, Endler NS, Lee PS, et al. A meta-analysis of treatments for panic disorder with agoraphobia: imipramine, alprazolam, and in vivo exposure. J Behav Ther Exp Psychiatry 1992;23:75-182
35. Van Balkom AJ, Bakker A, Spinhoven P, et al. A meta-analysis of the treatment of panic disorder with or without agoraphobia: a comparison of psychopharmacological, cognitive-behavioral, and combination treatments. J Nerv Ment Dis 1997;185:510-516
36. Keller MB, Lavori PW, Goldenberg IM, et al. Influence of depression on the treatment of panic disorder with imipramine, alprazolam and placebo. J Affect Disord 1993;28:27-38
37. Clum GA, Clum GA, Surls R. A meta-analysis of treatments for panic disorder. J Consult Clin Psychol 1993;61:317-326